<DOC>
	<DOCNO>NCT00213031</DOCNO>
	<brief_summary>The primary aim study assess safety acceptability PC-515 apply vaginally least three time weekly 12 month . Secondary aim gather preliminary data Carraguard ’ effectiveness prevent male-to-female transmission HIV , STIs . The hypothesis Carraguard would cause little significant irritation , include lesion ; woman would find Carraguard acceptable . The study power determine effectiveness , base safety , acceptability feasibility parameter , outcome Phase 2 trial would enable decision whether proceed Phase 3 trial .</brief_summary>
	<brief_title>Safety , Acceptability Preliminary Effectiveness PC-515 Vaginal Use Possible Microbicide</brief_title>
	<detailed_description>Carraguard™ ( PC-515 ) , Population Council ’ lead candidate microbicide , test triple-masked , randomize , placebo-controlled trial field one site Chiang Rai , northern Thailand . The primary aim study assess Carraguard ’ safety ( toxicity ) – include sign local irritation , itch burning ; change vaginal flora ; incidence abnormal external genital , vaginal , cervical finding – apply vaginally 12 month ; evaluate acceptability ; ass feasibility conduct large scale microbicide trial non-sex worker population ; gauge woman ’ reaction non-contraceptive microbicide ; explore microbicide use dynamic Thai population . Secondary aim investigate HIV infection avert ( preliminary indication ) ; sexually transmit infection avert – include C. trachomatis , N. gonorrhoeae , T. vaginalis , T. pallidum ( preliminary indication ) ; effect cervical cytology .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Syphilis</mesh_term>
	<mesh_term>Gonorrhea</mesh_term>
	<mesh_term>Trichomonas Infections</mesh_term>
	<mesh_term>Trichomonas Vaginitis</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>In good health determine medical history , physical examination result laboratory screening test Aged 18 year old Resident area least one year planning stay least 12 month HIVseronegative baseline Willing able comply study protocol ( include test HIV , learn result , undergo clinical evaluation ) Able achieve score 80 % good truefalse test key study concept Able give inform consent Pregnant desire become pregnant time study participation Delivered abort pregnancy within six week prior screen Male sex partner know enrollment HIV positive History surgery external genitalia , vagina cervix six week prior screen Recent history nonmenstrual vaginal bleeding intercourse Clinically detectable genital abnormality ( include presence wart , structural congenital abnormality ) Clinical suspicion reproductive tract infection ( RTI ) , define presence genital ulcer visible naked eye , abnormal vaginal discharge purulent cervicitis , untreated positive STD result ( Women could enrol treatment identify RTI . Women persistent genital epithelial disruption , i.e. , ulcer , abrasion fissure , eligible . Women persistent abnormal sign , vaginal cervical discharge , despite treatment identify RTI , eligible ) Abnormal Pap smear ( Class II ) History sensitivity/allergy latex Concurrent participation another trial vaginal product Injection recreational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>microbicides</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>sexually transmit infection</keyword>
	<keyword>female-initiated protection</keyword>
	<keyword>carrageenan</keyword>
	<keyword>expand safety trial</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV</keyword>
</DOC>